Emory University School of Medicine Researcher Adds New Study Findings to Research in Lymphoma [Extended Follow up and Immune Alterations in Patients with Classic Hodgkin Lymphoma (cHL) Treated with Frontline Single Agent Pembrolizumab Followed ...]

    Press/Media: Press / Media

    PeriodDec 25 2024